Pentostatin for High Risk and Refractory Chronic Graft Versus Host Disease in Children

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions
Graft vs Host Disease
Interventions
DRUG

Pentostatin

The drug, Pentostatin, is given every 2 weeks. This drug will be given by intravenous (IV) infusion.

Trial Locations (25)

10595

New York Medical College, Valhalla

17033

Penn State Milton S. Hershey Medical Center, Hershey

19104

Children's Hospital of Philadelphia, Philadelphia

21287

John's Hopkins, Baltimore

30322

Children's Healthcare of Atlanta, Atlanta

32007

Nemour's Children's Clinic, Jacksonville

33136

University of Miami, Miami

33701

All Children's Health System, St. Petersburg

43205

Columbus Children's Hospital, Columbus

44106

Rainbow Babies and Children's, Cleveland

46202

Riley Hospital for Children, Indianapolis

48109

University of Michigan, Ann Arbor

49503

DeVos Children's Hospital, Grand Rapids

60614

Children's Memorial Hospital, Chicago

63104

St. Louis University, St Louis

64108

Children's Mercy Hospital, Kansas City

70112

LSUHSC, New Orleans

75390

Victor Aquino, MD, Dallas

76104

Cook Children's Medical Center, Fort Worth

78229

Southwest Texas Methodist Hospital, San Antonio

84132

University of Utah, Salt Lake City

92350

Loma Linda University Medical Center, Loma Linda

94609

Pediatric Medical Center for Northern California, Oakland

07602

Hackensack University Medical Center, Hackensack

10032-3702

Columbia Presbyterian Medical Center, New York

Sponsors
All Listed Sponsors
collaborator

Astex Pharmaceuticals, Inc.

INDUSTRY

lead

Ann & Robert H Lurie Children's Hospital of Chicago

OTHER